Human papillomavirus infection among women with cytological abnormalities in Switzerland investigated by an automated linear array genotyping test

Limited data are available describing human papillomavirus (HPV) genotype distribution among females with cytological abnormalities in Switzerland. Cervical cell specimens obtained from 5,318 women were screened routinely by liquid‐based Pap smear. All specimens with cellular abnormalities were analyzed subsequently for HPV DNA by the Linear Array HPV genotyping test. Cellular abnormalities were found in 202 (3.8%) specimens, of which 150 (74.3%) were positive for high‐risk (HR) HPV. HR‐HPV was detected in 20 (60.6%; 95% CI, 43.7–75.4%) of 33 specimens with atypical squamous cells of undetermined significance compared to 98 (72.1%; 95% CI, 64–78.9%) of 136 low‐grade squamous intraepithelial lesions and 32 (97%; 95% CI, 83.4–99.9%) of 33 high‐grade squamous intraepithelial lesions. The cumulative prevalence of HR‐HPV other than HPV 16 and 18 was significantly higher than HPV 16 and/or 18 lesions with atypical squamous cells and low‐grade lesions and was comparable in high‐grade squamous intraepithelial lesions. The most common HR‐HPV genotypes were HPV 16 (15.2%), HPV 31 (12.1%), HPV 58 (12.1%), HPV 51 (9.1%), and HPV 59 (9.1%) in women with atypical squamous cells, HPV 16 (25%), HPV 51 (16.9%), HPV 52 (11.8%), HPV 31 (9.6%), and HPV 56 (8.1%) in women with low‐grade lesions (LSIL) and HPV 16 (57.6%), HPV 18 (18.2%), HPV 31 (15.2%), HPV 52 (12.1%), and HPV 58 (6.1%) in women with high‐grade lesions (HSIL). J. Med. Virol. 83:1370–1376, 2011. © 2011 Wiley‐Liss, Inc.

[1]  J. Cuzick,et al.  Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older , 2009, International journal of cancer.

[2]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[3]  S. Franceschi,et al.  Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[4]  E. Panotopoulou,et al.  Prevalence of human papillomavirus types 6, 11, 16, 18, 31, and 33 in a cohort of Greek women , 2007, Journal of medical virology.

[5]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[6]  F. Goffin,et al.  Age‐related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma screening in a population with a low incidence of cervical carcinoma , 2005, Cancer.

[7]  P. Castle,et al.  Five-Year Experience of Human Papillomavirus DNA and Papanicolaou Test Cotesting , 2009, Obstetrics and gynecology.

[8]  G. Duverlie,et al.  Prevalence of HPV genotypes determined by PCR and DNA sequencing in cervical specimens from French women with or without abnormalities. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  C. Wheeler,et al.  Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States , 2009, Journal of the National Cancer Institute.

[10]  A. Mohar,et al.  Epidemiology of Cervical Cancer , 2000, Cancer investigation.

[11]  W. Quint,et al.  Prevalence of low‐risk and high‐risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: An epidemiological observational study , 2010, Journal of medical virology.

[12]  P. Cassinotti,et al.  Automation of the linear array HPV genotyping test and its application for routine typing of human papillomaviruses in cervical specimens of women without cytological abnormalities in Switzerland. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  Philippe Vielh,et al.  Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening , 2003, BMJ : British Medical Journal.

[14]  J. Cuzick,et al.  Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial , 2007, BMJ : British Medical Journal.

[15]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[16]  P. Halfon,et al.  Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  S. Franceschi,et al.  Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update , 2007, International journal of cancer.

[18]  N. Muñoz,et al.  Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. , 2007, The Lancet. Infectious diseases.

[19]  H W Jones,et al.  Impact of the Bethesda System. , 1995, Cancer.

[20]  N. Segnan,et al.  European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Vicki B Benard,et al.  Cervical Screening in the National Breast and Cervical Cancer Early Detection Program, 1995–2001 , 2004, Obstetrics and gynecology.

[22]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.

[23]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[24]  A. Concha,et al.  Human Papillomavirus (HPV) Type Distribution in Females with Abnormal Cervical Cytology. A Correlation with Histological Study , 2009, The open virology journal.

[25]  M. R. Lipsi,et al.  Prevalence and genotypes identification of human papillomavirus infection in a population of South Italy. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[26]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[27]  S. Garland,et al.  Comparison of the Digene Hybrid Capture 2 Assay and Roche AMPLICOR and LINEAR ARRAY Human Papillomavirus (HPV) Tests in Detecting High-Risk HPV Genotypes in Specimens from Women with Previous Abnormal Pap Smear Results , 2007, Journal of Clinical Microbiology.

[28]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[29]  Nereo Segnan,et al.  Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial , 2007, BMJ : British Medical Journal.

[30]  A. Agresti,et al.  Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions , 1998 .